News

May 18, 2023

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

Cheyney, PA, May 18, 2023 — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing new criteria for antibody-drug conjugate...

 

Read More

April 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Meeting

NAV-001 and NAV-003 both target mesothelin, a cell surface protein over-expressed on various malignancies. Certain ADCs and therapeutic antibodies targeting mesothelin are negatively affected by Humoral Immuno-Oncology (HIO) factors...

 

Read More

March 27, 2023

Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness

Navrogen has established a research collaboration with the U.S. National Cancer Institute to study the potential role of Cancer Antigen-125 (CA125) in causing immunosuppression in patients with hematologic cancers,...

 

Read More

November 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes...

 

Read More

March 28, 2022

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London

Navrogen has presented new preclinical data on its NAV-001 antibody-drug conjugate (ADC) program at the 12th World ADC Conference in London, UK, on Wednesday, March 30th.

 

Read More

November 30, 2021

Navrogen Announces Publication of its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers

Navrogen announced today the publication of preclinical data regarding application of its proprietary Block-Removed Immunoglobulin Technology (BRITE) to enhance the efficacy of the CD20-targeting rituximab antibody in the presence...

 

Read More

September 13, 2021

Navrogen Enters into CRADA with USAMRIID to Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection

Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID)....

 

Read More

August 17, 2021

Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents

Navrogen and Tavotek will collaborate on the development of future Tavotek oncology assets while utilizing Navrogen’s proprietary screening technology to identify mAb leads that are susceptible to Humoral Immuno-Oncology...

 

Read More

August 9, 2021

Navrogen Closes $3.0M Seed Financing to Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers and Immune-Related Disorders

Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical...

 

Read More

July 1, 2021

Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed Cancers

Navrogen has signed a commercial evaluation license agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for the commercialization of tumor targeted therapies to...

 

Read More